ROVI is a specialized pharmaceutical company engaged in the research, development, manufacturing and marketing of pharmaceutical products.
Its operations encompass the marketing of both its own and licensed products and the provision of services, such as production, filling, packaging and running clinical trials for other companies.
On 7th of March, 2017. Laboratorios Farmacéuticos ROVI, S.A received the positive outcome of the marketing authorization application of a low molecular weight heparin (enoxaparin biosimilar) in twenty-six countries of the European Union (Lithuania not included). The Decentralised procedure (DCP) used Germany as Reference Member State. The first country in Europe where Enoxaparin biosimilar has been launched has been Germany in September 2017 and in March 2018 was launched in the UK market.
More than 70 years researching and improving health, find out our major milestones
Foundation of the Company
Beginning of research into low-molecular-weight heparins
Launch of Bemiparin (ROVI's own development LMWH) on the Spanish Market
Internationalization of ROVI following
approval of Bemiparin outside Spain
Increased International coverage
to 56 countries
Construction of the Granada R&D&i
centre and plant
FDA certification of the
Registration process for an
enoxaparin biosimilar with the EU
Adquisition of the new injectables plant
in San Sebastián de los Reyes
Successful completion of the
procedure to apply for authorization to market
an enoxaparin biosimilar in 26 EU countries
The development of a biosimilar of enoxaparin is a logical evolution of ROVI business. With the biosimilar of enoxaparin, ROVI is aiming to become one of the European top players in a €1Bn market. ROVI will increase its footprint also in emerging markets with a potential market of Eur 0.5Bn sales.
ROVI has a significant competitive advantage in the Enoxaparin market thanks to its vertical integration.